← Back to Calendar
Live Company Data
NCM
Updated
just now
· Data: FMP
Current Price
$14.80
+12.72%
+$1.67 today
Day: $14.70 – $15.15
Market Cap
N/A
Shares out: 102.21M
Float: 102.15M
52-Week Range
Current price is at 13% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Active thyroid eye disease (TED) — subcutaneous anti-FcRn antibody
Key Notes
REVEAL-1 Phase 3 topline data POSITIVE (announced March 30, 2026): elegrobart (VRDN-003) met primary endpoint in active TED — significant proptosis reduction vs placebo. REVEAL-2 topline data expected Q2 2026. elegrobart is a subcutaneous next-generation anti-FcRn antibody for active TED — separate from IV veligrotug (PDUFA June 30, 2026). BLA submission for subQ elegrobart planned end of 2026. Successful REVEAL-1 + REVEAL-2 would set up Viridian with both IV and subcutaneous TED therapies. Company confirmed enrollment exceeded targets.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.